Glaucoma research focuses on neurodegeneration
November 26th 2008The growing understanding that glaucoma is a neurodegenerative rather than ocular disease is to be the principal topic of discussion of the annual Glaucoma Research Foundation (GRF) benefit, to be held January 28 2009 in San Francisco, California, US.
Vitrectomy drug alternative continues to impress
November 26th 2008The Phase IIb trial assessing the safety and efficacy of microplasmin in patients, showed complete resolution of vitreomacular traction or macular hole without need for vitrectomy surgery, according to a statement from the trial sponsor, ThromboGenics NV.
Retina Regeneration Therapy effective in ME
November 17th 2008Ellex's 2RT, a Retina Regeneration Therapy, is safe and effective in the treatment of macular oedema (ME) secondary to diabetic retinopathy (DR), according to study results presented at this year's American Academy of Ophthalmology meeting.
Potentia unveils AMD drug results
November 17th 2008A Phase I trial of POT-4, a complement inhibitor in development for the treatment of age-related macular degeneration (AMD), have demonstrated that the agent is safe and well tolerated. The results were presented by Potentia Pharmaceuticals during the Retina Subspecialty Day at the meeting of the American Academy of Ophthalmology.
Telescope still effective at two years
November 10th 2008The Implantable Miniature Telescope (IMT) from VisionCare for end-stage age-related macular degeneration (AMD) maintains best-corrected visual acuity (BCVA) improvements to two years, according to results published in the November edition of the American Journal of Ophthalmology.
Anti-VEGFs may cause blindness
November 10th 2008Long-term use of anti-vascular endothelial growth factor (VEGF) drugs should be treated with caution, as endogenous VEGF plays an important role in the maintenance of retina neuronal cells, according to study results published by PLoS ONE on November 3.
Assessing human error rates in strabismus surgery
November 3rd 2008Sensitivity analysis could determine the rate of human error in strabismus surgery and reduce the need for repeated operations, according to results published online ahead of print by Graefe's Archive for Clinical and Experimental Ophthalmology.
Glaucoma therapy mode of actions compared
November 3rd 2008Although both latanoprost and timolol-dorzolamide fixed combination (TDFC) decrease 24-hour intraocular pressure (IOP) and enhance diastolic ocular perfusion pressure (DOPP) in primary open-angle glaucoma (POAG) patients, their mechanisms of action are different, according to study results published online by Investigative Ophthalmology and Visual Science.